Akari Therapeutics (AKTX) Intangibles (2014 - 2026)
Akari Therapeutics recorded quarterly Intangibles of $30.3 million in Q1 2026, down 10.88% quarter-over-quarter from $34.0 million in Q4 2025, and down 22.66% year-over-year from $39.2 million in Q1 2025.
Akari Therapeutics' Intangibles history runs 13 years deep, the most recent figure standing at $30.3 million for Q1 2026.
- In Q1 2026, Intangibles fell 22.66% year-over-year to $30.3 million; the TTM figure through Mar 2026 stood at $30.3 million (down 22.66% YoY), while the FY2025 annual figure was $34.0 million, down 13.22% from the prior year.
- Intangibles came in at $30.3 million for Q1 2026 at Akari Therapeutics, down from $34.0 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $39.2 million in Q4 2024 to a low of $14000.0 in Q4 2023.
- A 5-year average of $27.0 million and a median of $34.0 million in 2025 frame the typical range for Intangibles.
- Across the five-year window, Intangibles surged 279757.14% in 2024 and dropped 22.66% in 2026, its largest moves.
- Akari Therapeutics' Intangibles stood at $17000.0 in 2022, then fell by 17.65% to $14000.0 in 2023, then soared by 279757.14% to $39.2 million in 2024, then fell by 13.22% to $34.0 million in 2025, then slipped by 10.88% to $30.3 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $30.3 million, $34.0 million, and $34.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.41 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 11,640.44 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 418.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.29 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 55.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.30 Mn |
| Dec 31, 2025 | 34.00 Mn |
| Sep 30, 2025 | 34.00 Mn |
| Jun 30, 2025 | 39.18 Mn |
| Mar 31, 2025 | 39.18 Mn |
| Dec 31, 2024 | 39.18 Mn |
| Dec 31, 2023 | 14,000.00 |
| Dec 31, 2022 | 17,000.00 |
| Dec 31, 2021 | 23.00 |
| Dec 31, 2020 | 27.00 |
| Sep 30, 2020 | 26,674.00 |
| Jun 30, 2020 | 26,489.00 |
| Mar 31, 2020 | 27,566.00 |
| Dec 31, 2019 | 30.00 |
| Sep 30, 2019 | 29,147.00 |
| Jun 30, 2019 | 31,065.00 |
| Mar 31, 2019 | 32,867.00 |
| Dec 31, 2018 | 33.00 |
| Dec 31, 2017 | 36.00 |
| Dec 31, 2016 | 39,365.00 |
| Mar 31, 2016 | 49,019.00 |
| Dec 31, 2015 | 52.00 |
| Sep 30, 2015 | 58,099.00 |
| Dec 31, 2014 | 59,417.00 |